A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Purpose
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Condition
- Obesity
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
Exclusion Criteria
- Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening. - Have a prior or planned surgical treatment for obesity. - Have a prior or planned endoscopic procedure and/or device-based therapy for obesity. - Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. - Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2). - Have had within the past 90 days before screening: - acute myocardial infarction - cerebrovascular accident (stroke) - coronary revascularization - hospitalization for unstable angina, or - hospitalization due to congestive heart failure. - Have New York Heart Association Functional Classification Class IV congestive heart failure. - Have a history of chronic or acute pancreatitis.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Retatrutide |
Participants will receive retatrutide administered subcutaneously (SC) |
|
|
Active Comparator Tirzepatide |
Participants will receive tirzepatide administered SC |
|
Recruiting Locations
More Details
- NCT ID
- NCT06662383
- Status
- Active, not recruiting
- Sponsor
- Eli Lilly and Company